All In Biotech

Drug Trial Radar · NCT05342623

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension

Last checked: Nov 19, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

286

Actual

Start

May 17, 2022

Primary completion

Feb 29, 2024

Study completion Feb 29, 2024

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind 12-week Treatment Period (Treatment Period 1), and the Long-term Extension Phase includes a double-blind Treatment Period (Treatment Period 2) of up to 52 weeks.

Conditions

  • Chronic Kidney Diseases
  • Pruritus

Interventions

  • Difelikefalin 1 mg Oral TabletDrug

    Difelikefalin 1 mg medication taken orally 1 time/day

  • Placebo Oral TabletDrug

    Placebo tablet taken orally 1 time/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects achieving at least a 4-point improvement from baseline with respect to the weekly mean of the daily 24-hour WI-NRS score at Week 12 of Treatment Period 1Time frame: Week 12 of Treatment Period 1

Locations

83 sites in 1 country. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Huntsville, Alabama

  • Cara Therapeutics Study Site

    Phoenix, Arizona

  • Cara Therapeutics Study Site

    Surprise, Arizona

  • Cara Therapeutics Study Site

    Anaheim, California

  • Cara Therapeutics Study Site

    Bakersfield, California

  • Cara Therapeutics Study Site

    Beverly Hills, California

  • Cara Therapeutics Study Site

    Chula Vista, California

  • Cara Therapeutics Study Site

    El Centro, California

  • Cara Therapeutics Study Site

    Garden Grove, California

  • Cara Therapeutics Study Site

    La Mesa, California

  • Cara Therapeutics Study Site

    Northridge, California

  • Cara Therapeutics Study Site

    Ontario, California

  • Cara Therapeutics Study Site

    Riverside, California

  • Cara Therapeutics Study Site

    Santa Clara, California

  • Cara Therapeutics Study Site

    South Gate, California

  • Cara Therapeutics Study Site

    Tarzana, California

  • Cara Therapeutics Study Site

    Vacaville, California

  • Cara Therapeutics Study Site

    Valencia, California

  • Cara Therapeutics Study Site

    Victorville, California

  • Cara Therapeutics Study Site

    Arvada, Colorado

  • Cara Therapeutics Study Site

    Denver, Colorado

  • Cara Therapeutics Study Site

    New Haven, Connecticut

  • Cara Therapeutics Study Site

    Atlantis, Florida

  • Cara Therapeutics Study Site

    Cape Coral, Florida

  • Cara Therapeutics Study Site

    Coral Gables, Florida

  • Cara Therapeutics Study Site

    Fort Lauderdale, Florida

  • Cara Therapeutics Study Site

    Hialeah, Florida

  • Cara Therapeutics Study Site

    Miami, Florida

  • Cara Therapeutics Study Site

    Miami, Florida

  • Cara Therapeutics Study Site

    Orange City, Florida

  • Cara Therapeutics Study Site 2

    Orlando, Florida

  • Cara Therapeutics Study Site

    Orlando, Florida

  • Cara Therapeutics Study Site

    Pembroke Pines, Florida

  • Cara Therapeutics Study Site

    Riverview, Florida

  • Cara Therapeutics Study Site

    Tampa, Florida

  • Cara Therapeutics Study Site

    West Palm Beach, Florida

  • Cara Therapeutics Study Site

    Albany, Georgia

  • Cara Therapeutics Study Site

    East Point, Georgia

  • Cara Therapeutics Study Site

    Nampa, Idaho

  • Cara Therapeutics Study Site

    Huntley, Illinois

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.